Rangeley Capital LLC Sells 40,484 Shares of Monte Rosa Therapeutics, Inc. $GLUE

Rangeley Capital LLC cut its stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 60.0% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,016 shares of the company’s stock after selling 40,484 shares during the quarter. Rangeley Capital LLC’s holdings in Monte Rosa Therapeutics were worth $444,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC bought a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at approximately $30,000. Russell Investments Group Ltd. bought a new position in Monte Rosa Therapeutics in the third quarter worth approximately $32,000. Lazard Asset Management LLC increased its holdings in Monte Rosa Therapeutics by 42.9% during the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after purchasing an additional 3,262 shares during the period. Nisa Investment Advisors LLC increased its holdings in Monte Rosa Therapeutics by 16.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after purchasing an additional 776 shares during the period. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Performance

Shares of NASDAQ GLUE opened at $22.78 on Monday. The stock has a market capitalization of $1.92 billion, a PE ratio of -15.39 and a beta of 1.56. The stock’s fifty day simple moving average is $20.61 and its two-hundred day simple moving average is $19.65. Monte Rosa Therapeutics, Inc. has a 12-month low of $4.12 and a 12-month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. On average, equities analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Zacks Research cut Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. upped their price objective on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Guggenheim increased their target price on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $33.33.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, Director Anthony M. Manning sold 10,000 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the transaction, the director directly owned 10,000 shares in the company, valued at approximately $231,100. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Sharon Townson sold 6,000 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the sale, the insider directly owned 67,845 shares of the company’s stock, valued at approximately $1,581,466.95. The trade was a 8.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,778 shares of company stock worth $1,768,581 in the last three months. 6.40% of the stock is owned by company insiders.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.